Mantle Cell Lymphoma | Specialty

Ibrutinib Boosts the Activity of Second CD19-Directed CAR T-Cell Therapy in Refractory Non-Hodgkin Lymphoma

May 13th 2021

A second treatment with CD19-directed CAR T-cell therapy plus ibrutinib (Imbruvica) following failed prior CD19-directed CAR T-cell therapy and salvage treatment with ibrutinib led to greater efficiency and anti-CD19 CAR T-cell amplification, but also higher grades of cytokine release syndrome and more serious hematologic toxicity in patients with refractory B-cell non-Hodgkin lymphoma.

Ixazomib/Ibrutinib Combo Could Enhance Single-Agent BTK Inhibitor Efficacy in Relapsed/Refractory MCL

May 13th 2021

The ongoing, phase 1/2 PrE0404 trial is evaluating the combination of ixazomib and ibrutinib in patients with relapsed/refractory mantle cell lymphoma with the goal of improving upon single-agent BTK inhibitor therapy in this patient population.

Acalabrutinib Elicits Early Activity in a Japanese Population With B-Cell Malignancies

May 12th 2021

Acalabrutinib elicited early antitumor activity with acceptable tolerability in a population of Japanese patients with relapsed/refractory B-cell malignancies.

Dr. Alkharabsheh on Ongoing Research Efforts Examining Novel Combos in MCL

May 10th 2021

Omar Alkharabsheh, MD, discusses ongoing research efforts examining combination therapies in patients with mantle cell lymphoma.

Dr. Goy on the Durability of Response With Brexucabtagene Autoleucel in MCL

May 6th 2021

Andre H. Goy, MD, discusses the durability of response with brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Skarbnik on the Optimization of CAR T-Cell Therapy Sequencing in MCL

April 22nd 2021

Alan P. Z. Skarbnik, MD, discusses the optimization of treatment sequencing with CAR T-cell therapy in mantle cell lymphoma.

CAR T-Cell Therapy Makes a Splash in MCL, But Optimal Sequencing Remains an Open Question

April 20th 2021

The FDA approval of brexucabtagene autoleucel established CAR T-cell therapy as a treatment option for patients with relapsed/refractory mantle cell lymphoma.

Dr. Goy on the Potential Utility of Liso-Cel in MCL

April 19th 2021

Andre H. Goy, MD, discusses the potential utility of lisocabtagene maraleucel in mantle cell lymphoma.

Tazemetostat Displays Promising Preclinical Activity in BTK-Resistant MCL Cell Lines

April 16th 2021

Tazemetostat as a single agent or in combination with zanubrutinib demonstrated antitumor activity in mantle cell lymphoma cell lines with intrinsic resistance to BTK inhibitors, suggesting that the agent could be a promising therapeutic option for patients with primary relapsed/refractory disease.

Dr. Till on Data With Liso-Cel Vs Other Products Under Examination in MCL

April 14th 2021

Brian Till, MD, discusses the safety and efficacy of lisocabtagene maraleucel compared with other products under exploration in patients with mantle cell lymphoma.